UPDATE: Alterity Therapeutics (ATHE) - The Regulatory Coil Tightens, and a New Scale Quietly Solves the 75mg Problem

Two FDA disciplines aligned, an AAN late-breaker that reframes the messy Phase 2, and a commercial-strategy hire — the stock is up 27.8% for a reason.

When I wrote up Alterity in early March, my thesis hinged on one binary event: the mid-2026 End-of-Phase 2 (EOP2) meeting and whether the FDA would let them carry that 48% relative treatment effect at 50mg into a registrational Phase 3 without forcing a massive, stratified, cash-incinerating redesign. Three things happened since: a Type C meeting cleared two of the four regulatory disciplines, a late-breaker at AAN introduced a new MSA outcome scale (MuSyCA) that independently reproduces the efficacy signal at both doses, and the board added a commercial-launch operator. The stock is +27.8% (from $3.45 on March 2 to $4.41 on April 24) and that move is, for once, mechanically justified.

This is not a thesis change. It is a thesis tracking — and the regulatory coil is winding tighter into mid-year.